Isp Final Gr Presentation

Gedeon Richter,[object Object],Producing the Next Generation of Generics,[object Object],Erica Chau | Andy Chiu | Nicole Lee | Lisa Liu | Haonan Zhang,[object Object]

Agenda,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object]

Market Position,[object Object],Composition of Global Pharmaceutical Market,[object Object],CAGR 2004-08 (%),[object Object],Pfizer,[object Object],Bayer,[object Object],40,[object Object],Servier,[object Object],30,[object Object],Gedeon Richter,[object Object],GlaxoSmith Kline,[object Object],20,[object Object],Sales growth 2007-08 (%),[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object],Zentiva,[object Object],Novartis,[object Object],Sanofi-Aventis,[object Object],10,[object Object],Krka,[object Object],5 10 15 20 25 ,[object Object]

Sales Composition,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object]

SWOT Analysis,[object Object],Strengths,[object Object],Opportunities,[object Object],Weaknesses,[object Object],Threats,[object Object],[object Object]

Strong position in gynecological drug market

Long-term value in biosimilars

Potential growth in branded products and OTC medicines

Increasing focus on generic drugs

Size of firm limits extensive global expansion

Sales are highly correlated with stability of CIS region

Stricter governmental policies and regulations

Increasing competition in generic market and downward pricing pressuresThe Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object]

Rising Health Care Costs,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object]

Industry Structure Shift ,[object Object],Traditional Pharmaceutical Industry,[object Object],New Pharmaceutical Industry,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object],Licensing deals & alliances,[object Object]

Industry Growth Comparison,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object]

Business Concerns,[object Object],Company facing increased pressure from the trend toward biosimilars,[object Object],Customers demanding less expensive generic drugs,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object]

Our Recommendations,[object Object],Prepare Gedeon Richter for industry trend toward biosimilars,[object Object],Company facing increased pressure from the trend toward biosimilars,[object Object],Customers demanding less expensive generic drugs,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object],Partner with biotech firm to develop biosimilar business,[object Object],Outsource generics manufacturing to India,[object Object]

Why Biosimilars?,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object]

What Are Biosimilars?,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object]

GR Experience in Biotech,[object Object],Management made a decision in 2006 to start recombinant biotechnological activities,[object Object],Gedeon Richter and Helm AG acquired Strathmann Biotech for R&D laboratory, pilot plant, and manufacturing unit,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object],Constructed a biotechnology plant in Budapest, operational in 2009,[object Object],Made a greenfield investment in manufacturing plant in Debrecen for mammalian cell development,[object Object]

Potential Partners,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object],Yes,[object Object],No,[object Object]

Shifting Focus,[object Object],The Company,[object Object],The Industry,[object Object],The Challenges,[object Object],Recommendations,[object Object],Conclusion,[object Object]

Isp Final Gr Presentation

Isp Final Gr Presentation

Recomendados

Más contenido relacionado

Was ist angesagt?

Was ist angesagt?(19)

Destacado

Destacado(17)

Similar a Isp Final Gr Presentation

Similar a Isp Final Gr Presentation(20)

Isp Final Gr Presentation

Hinweis der Redaktion